




PHARMACEUTICAL 2022

G1 Therapeutics Inc.
Rank 311 of 466





PHARMACEUTICAL 2022

G1 Therapeutics Inc.
Rank 311 of 466



The relative strengths and weaknesses of G1 Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of G1 Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 27% points. The greatest weakness of G1 Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 71% points.

The company's Economic Capital Ratio, given in the ranking table, is 54%, being 24% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	243,565
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	27,613
Liabilities, Non-Current	6,750
Other Assets	8,516
Other Compr. Net Income	0
Other Expenses	2,941
Other Liabilities	76,190
Other Net Income	-4,970
Other Revenues	31,476
Property and Equipment	2,013
Research and Development	76,225
Selling, General and Administrative Expense	95,692

Output Variable	Value in 1000 USD
Assets	254,094
Liabilities	110,553
Expenses	174,858
Revenues	31,476
Stockholders Equity	143,541
Net Income	-148,352
Comprehensive Net Income	-148,352
Economic Capital Ratio	54%